Market Cap 217.76B
Revenue (ttm) 64.17B
Net Income (ttm) 17.12B
EPS (ttm) N/A
PE Ratio 11.47
Forward PE 9.82
Profit Margin 26.68%
Debt to Equity Ratio 0.69
Volume 7,902,000
Avg Vol 12,144,796
Day's Range N/A - N/A
Shares Out 2.50B
Stochastic %K 77%
Beta 0.37
Analysts Sell
Price Target $102.05

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as liv...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 908 740 4000
Address:
126 East Lincoln Avenue, Rahway, United States
RevolvoR
RevolvoR Oct. 24 at 8:58 PM
$MRK golden cross? Is it time?
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 4:51 PM
$MRK Q3 preview — could non-oncology be the quiet growth engine? The company expects new launches like Capvaxive and Winrevair, plus solid Animal Health momentum, to help drive top-line growth this quarter. Full breakdown of what to expect here 👉 https://www.zacks.com/stock/news/2776474/mercks-non-oncology-drugs-q3-performance-what-to-expect?cid=sm-stocktwits-2-2776474-teaser-17567&ADID=SYND_STOCKTWITS_TWEET_2_2776474_TEASER_17567
0 · Reply
smartoptionstrader
smartoptionstrader Oct. 24 at 4:37 PM
MAIN POST: Big Pharma's M&A wave isn't slowing—it's accelerating into 2026. $MRK $JNJ $SNY desperately plugging patent cliff revenue holes. But here's the smarter play: $GS collects fees on every deal. Trading at $781 (15.5x earnings, below $SPY average) and $44 off September highs, Goldman is positioned perfectly. Lower rates, desperate acquirers, and frozen IPOs lead to more deals, resulting in more GS fees. Don't gamble on which biotech gets bought—follow the money to Wall Street's M&A king. Goldman Sachs Long-Term Price Chart (1997-2025) - Shows a steady upward trajectory with a September 2025 record high at $825, currently trading at $781. The chart demonstrates GS's consistent performance across multiple market cycles, validating the bullish technical setup with clear upside potential to new highs.
0 · Reply
StockOracle22
StockOracle22 Oct. 24 at 4:29 PM
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 3:51 PM
$MRK Q3 earnings on the horizon: Is it time to refocus on non-oncology growth? 🔍 With Keytruda's exclusivity set to expire in 2028, all eyes are on Merck's new drugs like Capvaxive and Winrevair, which showed strong uptake in 2025. Discover the full potential and competitive landscape for $MRK's pipeline here 👉 https://www.zacks.com/stock/news/2776474/mercks-non-oncology-drugs-q3-performance-what-to-expect?cid=sm-stocktwits-2-2776474-body-17554&ADID=SYND_STOCKTWITS_TWEET_2_2776474_BODY_17554
0 · Reply
Fredsavage911
Fredsavage911 Oct. 24 at 3:15 PM
0 · Reply
BirchTreeJJ
BirchTreeJJ Oct. 24 at 3:04 PM
$NEUP The reason why LYNX1 bought as many shares as they legally could buy the day the study failed is because he knows as a director the social anxiety study is NOT and was NEVER what this company was counting on. The ability to get data from a social anxiety or any pain study is nearly impossible. Everyone knows that. The failure rate is sky high The other drugs in their pipeline and the $450 million partnership with $MRK are what this company will eventually be valued for. And that will be a minimum of $20 a share. Conservatively.
0 · Reply
Aporia
Aporia Oct. 24 at 2:41 PM
$MRK holding q 2,3 highs; take out yearly highs, before eoy?
0 · Reply
BirchTreeJJ
BirchTreeJJ Oct. 24 at 2:29 PM
$NEUP Enough cash to run things into 2027 450 million +++ deal with $MRK Shares all tied up by insiders and smart money NO SHARES AVAILABLE TO TRADE OTHER THAN FAKE COMPUTER TRADES BY MARKET MAKERS
0 · Reply
clan
clan Oct. 24 at 1:37 PM
$MRK $JNJ $AMGN 😲 Okay, fess up! Who here knew there exists an ULTRA rapid-acting INHALABLE mealtime insulin for diabetics?!? Just WOW!
0 · Reply
Latest News on MRK
Merck Q3 Earnings Preview: Issues That Will Dominate The Agenda

Oct 24, 2025, 4:24 PM EDT - 15 hours ago

Merck Q3 Earnings Preview: Issues That Will Dominate The Agenda


My Top 3 Pharma Stocks

Oct 20, 2025, 11:38 AM EDT - 4 days ago

My Top 3 Pharma Stocks

AKRO BMY ETNB LLY NVO PFE SPY


Merck breaks ground on $3B manufacturing plant in Virginia

Oct 20, 2025, 6:56 AM EDT - 5 days ago

Merck breaks ground on $3B manufacturing plant in Virginia


Germany's Merck tweaks mid-term healthcare unit guidance

Oct 16, 2025, 1:04 AM EDT - 9 days ago

Germany's Merck tweaks mid-term healthcare unit guidance


Merck: A Golden Buying Opportunity

Oct 15, 2025, 3:43 PM EDT - 9 days ago

Merck: A Golden Buying Opportunity


Merck: An Undervalued Stock In An Expensive Market

Oct 13, 2025, 10:00 AM EDT - 11 days ago

Merck: An Undervalued Stock In An Expensive Market


High Margins, Lower Price: Is This Merck Stock's Buying Window?

Oct 10, 2025, 9:10 AM EDT - 14 days ago

High Margins, Lower Price: Is This Merck Stock's Buying Window?


Merck Completes Acquisition of Verona Pharma

Oct 7, 2025, 6:45 AM EDT - 18 days ago

Merck Completes Acquisition of Verona Pharma


How to trade the health care break out

Oct 6, 2025, 2:24 PM EDT - 18 days ago

How to trade the health care break out

MCK UNH VEEV XBI XLV


Merck: A Race Against The Keytruda Clock

Oct 3, 2025, 1:21 PM EDT - 21 days ago

Merck: A Race Against The Keytruda Clock


ABBV Stock vs. Eli Lilly & Merck

Oct 2, 2025, 8:20 AM EDT - 22 days ago

ABBV Stock vs. Eli Lilly & Merck

ABBV LLY


Merck: Game-Changing Oncology Drugs Power Stock Surge

Sep 26, 2025, 11:46 AM EDT - 4 weeks ago

Merck: Game-Changing Oncology Drugs Power Stock Surge


RevolvoR
RevolvoR Oct. 24 at 8:58 PM
$MRK golden cross? Is it time?
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 4:51 PM
$MRK Q3 preview — could non-oncology be the quiet growth engine? The company expects new launches like Capvaxive and Winrevair, plus solid Animal Health momentum, to help drive top-line growth this quarter. Full breakdown of what to expect here 👉 https://www.zacks.com/stock/news/2776474/mercks-non-oncology-drugs-q3-performance-what-to-expect?cid=sm-stocktwits-2-2776474-teaser-17567&ADID=SYND_STOCKTWITS_TWEET_2_2776474_TEASER_17567
0 · Reply
smartoptionstrader
smartoptionstrader Oct. 24 at 4:37 PM
MAIN POST: Big Pharma's M&A wave isn't slowing—it's accelerating into 2026. $MRK $JNJ $SNY desperately plugging patent cliff revenue holes. But here's the smarter play: $GS collects fees on every deal. Trading at $781 (15.5x earnings, below $SPY average) and $44 off September highs, Goldman is positioned perfectly. Lower rates, desperate acquirers, and frozen IPOs lead to more deals, resulting in more GS fees. Don't gamble on which biotech gets bought—follow the money to Wall Street's M&A king. Goldman Sachs Long-Term Price Chart (1997-2025) - Shows a steady upward trajectory with a September 2025 record high at $825, currently trading at $781. The chart demonstrates GS's consistent performance across multiple market cycles, validating the bullish technical setup with clear upside potential to new highs.
0 · Reply
StockOracle22
StockOracle22 Oct. 24 at 4:29 PM
0 · Reply
ZacksResearch
ZacksResearch Oct. 24 at 3:51 PM
$MRK Q3 earnings on the horizon: Is it time to refocus on non-oncology growth? 🔍 With Keytruda's exclusivity set to expire in 2028, all eyes are on Merck's new drugs like Capvaxive and Winrevair, which showed strong uptake in 2025. Discover the full potential and competitive landscape for $MRK's pipeline here 👉 https://www.zacks.com/stock/news/2776474/mercks-non-oncology-drugs-q3-performance-what-to-expect?cid=sm-stocktwits-2-2776474-body-17554&ADID=SYND_STOCKTWITS_TWEET_2_2776474_BODY_17554
0 · Reply
Fredsavage911
Fredsavage911 Oct. 24 at 3:15 PM
0 · Reply
BirchTreeJJ
BirchTreeJJ Oct. 24 at 3:04 PM
$NEUP The reason why LYNX1 bought as many shares as they legally could buy the day the study failed is because he knows as a director the social anxiety study is NOT and was NEVER what this company was counting on. The ability to get data from a social anxiety or any pain study is nearly impossible. Everyone knows that. The failure rate is sky high The other drugs in their pipeline and the $450 million partnership with $MRK are what this company will eventually be valued for. And that will be a minimum of $20 a share. Conservatively.
0 · Reply
Aporia
Aporia Oct. 24 at 2:41 PM
$MRK holding q 2,3 highs; take out yearly highs, before eoy?
0 · Reply
BirchTreeJJ
BirchTreeJJ Oct. 24 at 2:29 PM
$NEUP Enough cash to run things into 2027 450 million +++ deal with $MRK Shares all tied up by insiders and smart money NO SHARES AVAILABLE TO TRADE OTHER THAN FAKE COMPUTER TRADES BY MARKET MAKERS
0 · Reply
clan
clan Oct. 24 at 1:37 PM
$MRK $JNJ $AMGN 😲 Okay, fess up! Who here knew there exists an ULTRA rapid-acting INHALABLE mealtime insulin for diabetics?!? Just WOW!
0 · Reply
BirchTreeJJ
BirchTreeJJ Oct. 24 at 1:08 PM
$NEUP due diligence done Based on $MRK deal alone this should easily be $20 a share. Conservatively Wow I’m so happy I found this Congrats to all who jumped in here lYNX1 now owns 40% of the float. It’s already a micro float. The tradable shares are insanely small This will catapult to $20 Possibly $10 today
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 3:37 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $MRK Current Share Price: $87.07 Contracts: $MRK December 18, 2026 $90 Calls Scale in: $8.27- $10.11 Scale out: $12.86-$16.54 Can Easily Capture: 60% ROI Blended DTE: 421 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
JenniferReyes7835
JenniferReyes7835 Oct. 23 at 10:06 PM
Breaking: momentum cluster forming — watch closely! Portfolio: $MGM $RIO $SLB $ABNB $MRK Why this cluster: Sector strength aligning with positive sentiment; disciplined entries and stops recommended. MGM shows relative strength; RIO is base-building; SLB is a stealth accumulator; ABNB offers sector exposure; MRK provides stability. Execution: Plan: small starter position, scale with a confirmed trend; respect risk. #AlphaHunt #Tactical Source:https://stocktwits.com/JacquelineBryant4972/message/632828478
0 · Reply
taxplanr
taxplanr Oct. 23 at 7:56 PM
$MRK $BMY EMF feeds and energizes Mitochondria not destroy it like malignantRNA
0 · Reply
RodneyOwens7668
RodneyOwens7668 Oct. 23 at 7:28 PM
High-conviction cluster — risk-defined entries only! Portfolio: $XOM $NVDA $MRK $NOV $LLY Why this cluster: Accumulation noted, range tightening, and cross-sector flow suggests rotation into these names. XOM shows relative strength; NVDA is base-building; MRK is a stealth accumulator; NOV offers sector exposure; LLY provides stability. Execution: Plan: small starter position, scale with a confirmed trend; respect risk. #TradeSetup #Watchlist Source:https://stocktwits.com/VeronicaWarren8662/message/632828887
0 · Reply
MusicBox
MusicBox Oct. 23 at 7:16 PM
Tape is smoking — catalysts near, volume rising! Portfolio: $JPM $MRK $DIS $TGT $WYNN Why this cluster: Liquidity profile looks favorable for quick repricing once momentum confirms. JPM shows relative strength; MRK is base-building; DIS is a stealth accumulator; TGT offers sector exposure; WYNN provides stability. Execution: Execution: define stop levels, use partial profit-taking on initial leg. #StocksToWatch #Momentum Source:https://stocktwits.com/FrederickSherman9600/message/632828598
0 · Reply
Buy_SoFi
Buy_SoFi Oct. 23 at 5:04 PM
$TLTFF $MRK $IBRX $CGON Potential NASDAQ listing rumored/expected? ---> $TLTFF
0 · Reply
Buy_SoFi
Buy_SoFi Oct. 23 at 5:03 PM
$TLTFF $MRK $IBRX $CGON NMIBC Phase II study about to complete enrolment. AMAZING numbers! (Potential FDA Accelerated Approval) ---> $TLTFF
0 · Reply
DannySmith6941
DannySmith6941 Oct. 23 at 4:56 PM
High-conviction cluster — risk-defined entries only! Portfolio: $FTNT $OKTA $MRK $REGN $ABNB Why this cluster: Sector strength aligning with positive sentiment; disciplined entries and stops recommended. FTNT shows relative strength; OKTA is base-building; MRK is a stealth accumulator; REGN offers sector exposure; ABNB provides stability. Execution: Tip: scale in with size discipline; add on volume-confirmed strength. #RiskManaged #TopPicks Source: https://stocktwits.com/JacquelineBryant4972/message/632828478
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 23 at 4:55 PM
$SLS This is the Math: dNPV 1,000 Institutional Fund Managers will be running NEXT week when they Realize Gps Immunotherapy is Getting FDA APPROVAL to treat 25,000 AML REMISSION PATIENTS. PSA: $ABBV/ $PFE or $MRK will be Paying a Premium to Include the AML CR1 Market - AZA+ VEN VIALE-M Just FAILED a 500 patient AML CR1 Phase 3 Maintenance Trial. AZA+VEN is the BAT for the SLS P3 Control ARM Patients AZA+VEN FAILED 3, Phase 3 AML Trials in the last few months - its toxic for the SLS P3 patients as well.
0 · Reply
SunAndStorm
SunAndStorm Oct. 23 at 4:37 PM
$XLV Started a position. XLV @ 145.84 is at 45% vs the predicted short term trading Opportunity Range™ for today. I also own $MRK and $JNJ, so adding to healthcare exp.
0 · Reply
Fredsavage911
Fredsavage911 Oct. 23 at 12:58 PM
$MRK Leronlimab (LL) a CCR5 inhibitor from Cytodyn (Cydy) was used in combination with checkpoint inhibitors…often Keytruda…in patients with metastatic triple negative breast cancer. LL increased PDL-1 allowing Keytruda to work in patients with previously cold tumors (tumors lacking PD-1/PDL-1). Below are initial results.
1 · Reply